Results
Clinicopathological features
Baseline characteristics and FUAS parameters of the 643 patients enrolled in this study are summarized in Table 1. The median follow-up time were 29 (2-62) months. 288 (55.2%) patients were included in FUAS group, while 355 (44.8%) patients were included in FUAS+ (combined with GnRH-a and/or mirena) group. The rates of endometriosis in FUAS group (18.7%) was higher than that in FUAS+ group (12.7%) (P﹤0.05), whereas there were no significant differences between two groups in terms of baseline characteristics and FUAS parameters (P>0.05, Table S1).